AXIOM SELENE

Evidence Library · Longevity & IV Therapy

Longevity & IV Therapy · AXIOM SELENE

NAD+ and IV Vitamin Therapy: What the Science Actually Shows (and Doesn't)

The marketing is enormous — clinics promise restored energy, cellular rejuvenation, and longevity. The human evidence, read carefully, is thin. Here is what is genuinely known, what remains uncertain, and which specific claims have no credible scientific support.

Evidence grade

Preliminary evidence — Single study or observational data — association, not proven causation

9 sources8 documented gapsLast verified: 2026-06-28

What NAD+ Is — the Biology That Is Not in Dispute

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It participates in energy metabolism (the conversion of nutrients to ATP), DNA repair processes, and the activation of proteins called sirtuins that regulate cellular stress responses. The molecule is real, biologically significant, and has been studied for decades. The question is not whether NAD+ exists or matters. The question is whether the marketed interventions — especially intravenous infusions — meaningfully change NAD+ levels in target tissues, and whether those changes produce the claimed benefits in healthy adults. On those two questions, the human evidence is far thinner than the marketing implies.

Does NAD+ Actually Decline with Age? The Evidence Is Contested

You will see this stated confidently in almost every clinic brochure: 'NAD+ levels decline with age.' The biology is plausible and the finding is real in certain animal tissues. In humans, the picture is more complicated than it is usually presented.

~ Probable (incomplete evidence)
NAD+ levels universally decline with age in human tissues — the core premise used to justify supplementation.

🅰 'Age-Dependent Decline of NAD+—Universal Truth or Confounded Consensus?' — PMC8747183 (2022 critical review)— A 2022 peer-reviewed critical review found that 'despite systematic claims of overall changes in NAD+ levels with aging, the evidence to support such claims is very limited.' Only two studies had directly measured NAD+ in human tissues during normal aging. Measurement estimates varied from no change to 80–90% reduction depending on method and tissue. The review concluded that larger, longitudinal studies are needed before decline can be called a 'universal truth.' The decline is better established in animal studies and in specific human tissues than as a generalised human fact.

Oral NAD+ Precursors (NMN / NR): What Human Trials Show

Most human research has focused on oral supplementation with NAD+ precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). A 2023 review identified 10 published human clinical trials of NMN. The findings are more modest than clinic marketing suggests, and the gap between 'blood levels rise' and 'health improves' has not been closed.

✓ Proven
Oral NMN supplementation raises NAD+ concentration in human blood.

🅰 'The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update' — PMC10721522 (2023 review of 10 published human NMN trials)— Consistent finding across trials: blood NAD+ rises 1–2.5 fold. This is a pharmacokinetic measurement, not a clinical outcome. Rising blood NAD+ does not establish that target tissues benefit, or that health outcomes improve.

~ Probable (incomplete evidence)
Oral NMN supplementation is safe in healthy adults at doses tested in short-term trials.

🅰 'The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update' — PMC10721522 (2023 review of 10 published human NMN trials)— No serious adverse events in published trials. However, most studies were short (weeks to a few months) and small (n=8–66). Long-term safety is not established.

✗ No evidence found
Oral NMN reverses aging, extends longevity, or meaningfully restores youthful cellular function in humans.

🅰 'The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update' — PMC10721522 (2023 review of 10 published human NMN trials)— No human trial has tested longevity or anti-aging outcomes at sufficient scale or duration. Individual signals (e.g., improved muscle function, insulin sensitivity in small cohorts) have been reported but not replicated in well-powered trials. The review authors explicitly caution against confident efficacy claims.

IV NAD+: What Actually Happens When You Infuse It

The commercial rationale for IV over oral is 100% bioavailability — bypassing gut absorption. The problem identified in research is that when IV NAD+ enters the bloodstream, enzymes called NAD+ glycohydrolases (including CD38) break it down rapidly before it can enter cells. A 2019 pilot study that directly measured the blood and urine metabolite profile during a 6-hour IV NAD+ infusion found the molecule was 'rapidly and completely removed from the plasma' within the first two hours — appearing mainly as breakdown products rather than intact NAD+.

✗ No evidence found
IV NAD+ directly enters cells and replenishes cellular NAD+ pools, justifying its advantage over oral supplementation.

🅰 'A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+' — PMC6751327 (2019, n=11)— The pilot study found that IV NAD+ is rapidly degraded by circulating enzymes into metabolites (nicotinamide, ADPR). Whether those breakdown products are later taken up by cells and reconverted to NAD+ is biologically plausible (the 'breakdown and salvage' hypothesis) but has not been demonstrated in human tissue. The assumption that IV provides a unique direct cellular benefit over oral precursors is not evidence-based.

✗✗ Evidence against
IV NAD+ infusions are comfortable and well-tolerated.

🅰 'Intravenous infusion of NAD+ versus NR: a retrospective tolerability pilot study in a real-world setting' — PMC12907335 (Frontiers in Aging, 2026, n=14)— A 2026 retrospective study at a commercial wellness clinic found that all 6 participants who received IV NAD+ reported moderate-to-severe abdominal cramping, diarrhoea, nausea, vomiting, increased heart rate, chest pressure, and throat pain during the infusion. Symptoms resolved on completion. NR IV was better tolerated but still caused tingling and mild cramping. Sample size was very small (n=14 total), and no placebo group was used.

IV Vitamin Drips More Broadly: The Myers' Cocktail Evidence

Beyond NAD+, the wellness IV market predominantly offers 'Myers' Cocktails' — mixtures of B vitamins, vitamin C, magnesium, and calcium administered intravenously. These have been marketed for general wellness since the 1970s. One randomised, double-blind, placebo-controlled trial has ever been published, testing Myers' Cocktail specifically for fibromyalgia pain. It did not find a significant benefit over placebo.

✗ No evidence found
Myers' Cocktail IV infusion produces significantly better outcomes than placebo in humans.

🅰 'Intravenous Micronutrient Therapy (Myers' Cocktail) for Fibromyalgia: A Placebo-Controlled Pilot Study' — PMC2894814 (2009, n=34, randomised double-blind)— n=34 adults with fibromyalgia. Both treatment and placebo groups improved meaningfully from baseline — a well-documented placebo effect of invasive procedures. No statistically significant difference between groups on any outcome measure. The researchers concluded that efficacy 'relative to placebo remains uncertain.' This is the only RCT for any Myers' Cocktail indication.

✗ No evidence found
IV delivery of vitamins produces better health outcomes than oral supplementation in healthy adults.

🅰 CADTH Rapid Review — 'Intravenous Multivitamin Therapy Use in Hospital or Outpatient Settings' (NCBI Bookshelf NBK567072, 2021)— A systematic review (CADTH 2021) searched 396 citations and found no evidence-based guidelines and no high-quality comparative evidence. Recommended future trials comparing IV to oral delivery before any conclusion can be drawn.

Sources in this section

What Medical Reference Sources Say

The Merck Manual — the standard professional medical reference — states there is 'insufficient scientific evidence that IV vitamin therapy has any of the above beneficial effects or is effective for treating any disease.' Cleveland Clinic functional medicine physicians note the therapy is offered at their facilities but describe its effectiveness as a general wellness tool as 'uncertain,' with their physician on record saying 'we're still looking for high-quality studies.' A 2025 peer-reviewed review concluded that claimed wellness benefits are 'primarily anecdotal or based on self-reported outcomes rather than well-designed randomized clinical trials.'

Sources in this section

Real Risks: What Every IV Procedure Carries

Every intravenous line breaks the skin barrier. This creates real risks: local infection or bruising at the injection site, phlebitis (inflammation of the vein), embolism (air or clot in a blood vessel), and in rare cases, systemic bloodstream infection (sepsis). The Merck Manual explicitly states that deaths have occurred from infections introduced via improperly sterilised equipment. High doses of fat-soluble vitamins (A, D, E, K) carry toxicity risk because they accumulate in the body. People with kidney disease, heart failure, or G6PD deficiency are at elevated risk and should not receive elective infusions without physician oversight. The Merck Manual also documents drug interactions: magnesium can potentiate blood pressure reduction with antihypertensives; calcium can damage kidneys or gallbladder when combined with certain antibiotics.

These risks are not unique to disreputable clinics. They are inherent to any intravenous procedure and apply in well-run settings too.

Sources in this section

What we don't yet know

Honesty about gaps in the evidence is what distinguishes us from most wellness media.

  • No randomised controlled trial has ever tested IV NAD+ for any wellness outcome — energy, longevity, cognitive performance, or anti-aging — in healthy adults. This is the single most important gap between what is marketed and what is scientifically tested.
  • Whether elevated NAD+ blood levels (confirmed by oral NMN/NR supplementation) actually increase NAD+ inside cells — particularly in brain, heart, or muscle — has not been demonstrated in humans.
  • Whether increasing NAD+ inside human cells would produce measurable clinical benefit has not been tested in any well-powered RCT for any endpoint.
  • No head-to-head human trial has compared IV NAD+ infusion to oral NMN or NR for any clinical outcome. The assumption that IV delivery is superior to oral supplementation is biologically speculative, not evidence-based.
  • Long-term safety of repeated IV NAD+ infusions is completely unstudied. All existing human IV NAD+ data covers single sessions or follow-up periods of 30 days or fewer.
  • The mechanism by which IV NAD+ might benefit cells — given that it is rapidly broken down by blood enzymes before cellular uptake — is not established in human tissue. The 'breakdown-and-salvage' hypothesis is plausible but unverified.
  • Optimal dosing, infusion rate, and frequency for IV NAD+ (or IV vitamin drips generally) have no evidence base for wellness applications in healthy people.
  • No studies on IV vitamin or NAD+ therapy specifically in tropical climates, or for wellness travellers to Thailand, were identified.

All sources

This article reviews published research for educational purposes only. It is not medical advice and does not constitute a recommendation for or against any treatment. IV infusions carry real medical risks inherent to any procedure that breaks the skin barrier and must only be undertaken under qualified medical supervision. People with kidney disease, heart failure, G6PD deficiency, or who take blood pressure medication, antibiotics, or other drugs should discuss risks with a physician before considering any infusion therapy.

Last verified: 2026-06-28 · ← Evidence Library